COMPANY Data
My FAVORITES

Movers and SHAKERS

Ticker | AXLA (Nasdaq) |
Current Price | $1.45 ↓ -0.03 |
Market Cap | 52.85M |
Price Target | *Refer to Report* |
Volume | 29.45k |
52wk Range | $1.35 - $5.90 |
ADVANCED MARKET DATA |

Advanced Market Data
Axcella Therapeutics (AXLA)840 Memorial Drive
Entrance on Blackstone Street, Third Floor
Cambridge, MA 2139
US
Overview
Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using endogenous metabolic modulator (EMM) compositions. The company’s product candidates are comprised of EMMs and derivatives that are engineered in distinct combinations and ratios to reset multiple biological pathways, improve cellular energetics, and restore homeostasis. Axcella’s pipeline includes lead therapeutic candidates in Phase 2 development for the reduction in risk of overt hepatic encephalopathy (OHE) recurrence, the treatment of Long COVID, and the treatment of non-alcoholic steatohepatitis (NASH). The company’s unique model allows for the evaluation of its EMM compositions through non-IND clinical studies or IND clinical trials. For more information, please visit www.axcellatx.com.
- Industry/Sector Report
- Corporate Presentation
- Corporate Events
- Press Releases/News Feed
- ChannelCAST Videos [1]
- Senior Equity Research Analyst
- Corporate Filings
Axcella Therapeutics Corporate Filings
Axcella Therapeutics Corporate Events
Axcella Therapeutics Press Releases / News Feed
Channelchek
Not available
Channelchek
No reports available